tradingkey.logo

Biofrontera Inc

BFRI
查看詳細走勢圖
0.766USD
+0.006+0.72%
收盤 12/19, 16:00美東報價延遲15分鐘
8.92M總市值
虧損本益比TTM

Biofrontera Inc

0.766
+0.006+0.72%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.72%

5天

-5.70%

1月

+1.65%

6月

+25.16%

今年開始到現在

-29.72%

1年

-21.72%

查看詳細走勢圖

TradingKey Biofrontera Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Biofrontera Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在藥品行業排名111/158位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價6.00。中期看,股價處於下降通道。近一個月,市場表現一般,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Biofrontera Inc評分

相關信息

行業排名
111 / 158
全市場排名
311 / 4582
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
6.000
目標均價
+628.77%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Biofrontera Inc亮點

亮點風險
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
業績高增長
公司營業收入穩步增長,連續3年增長30.16%
業績增長期
公司處於發展階段,最新年度總收入37.32M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入37.32M美元
估值合理
公司最新PE估值-0.51,處於3年歷史合理位
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉113.95K股

Biofrontera Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Biofrontera Inc簡介

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.
公司代碼BFRI
公司Biofrontera Inc
CEOLuebbert (Hermann)
網址https://www.biofrontera-us.com/

常見問題

Biofrontera Inc(BFRI)的當前股價是多少?

Biofrontera Inc(BFRI)的當前股價是 0.766。

Biofrontera Inc 的股票代碼是什麼?

Biofrontera Inc的股票代碼是BFRI。

Biofrontera Inc股票的52週最高點是多少?

Biofrontera Inc股票的52週最高點是1.870。

Biofrontera Inc股票的52週最低點是多少?

Biofrontera Inc股票的52週最低點是0.536。

Biofrontera Inc的市值是多少?

Biofrontera Inc的市值是8.92M。

Biofrontera Inc的淨利潤是多少?

Biofrontera Inc的淨利潤為-17.76M。

現在Biofrontera Inc(BFRI)的股票是買入、持有還是賣出?

根據分析師評級,Biofrontera Inc(BFRI)的總體評級為買入,目標價格為6.000。

Biofrontera Inc(BFRI)股票的每股收益(EPS TTM)是多少

Biofrontera Inc(BFRI)股票的每股收益(EPS TTM)是-1.506。
KeyAI